Clinical Trial Update: Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting safety, tolerability, and pharmacokinetics of intravenous RPX7009 in healthy adult subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• RPX7009

Snippet

Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Conditions: Healthy Volunteers, Bacterial Infections | Phase 1 | Status: COMPLETED